1. Зоткин Е.Г. Обзор основных клинических исследований алендроната. Соврем. ревматология. 2010; 1: 70–4.
2. Коршунов Н.И., Ершова О.Б., Белова К.Ю. Глюкокортикоидный остеопороз: диагностика и лечение. РМЖ. 2007; 6: 546–9.
3. Риггз Б.Л., Мелтон Л.Д. Остеопороз. Этиология, диагностика, лечение. М.: БИНОМ, 2000.
4. Adachi JD, Saag KG, Delmas PD et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001; 44: 202–11.
5. Boivin GY, Chavassieux PM, Santora AC et al. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000; 27 (5): 687–94.
6. Bone HG, Hosking D, Devogelaer JP et al. Alendronate Phase III Osteoporosis Treatment Study Group. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350 (12): 1189–99.
7. Bouvard B, Audran M, Legrand E, Chappard D. Ultrastructural characteristics of glucocorticoid-induced osteoporosis. Osteoporosis Int 2009; 20: 1089–92.
8. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporosis Int 2007; 18: 1319–28.
9. Cauley JA, Thompson DE et al. Risk of mortality following clinical fractures. Osteoporos Int 2000; 11: 556–61.
10. Davidson MR. Pharmacotherapeutics for osteoporosis prevention and treatment. J Midwifery Womens Health 2003; 48: 39–52.
11. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008; 83 (9): 1032–45.
12. Duque G, Rivas D. Alendronate has an anabolic effect on bone through the diff erentiation of mesenchymal stem cells. J Bone Miner Res 2007; 22 (10): 1603–11.
13. Fue L, Tang T, Miao Y. Stimulation of osteogenic differentiation and inhibition of adipogenic differentiation in bone marrow stromal cells by alendronate via ERK and JNK activation. Bone 2008; 43 (1): 40–7.
14. Greenspan S, Field-Munves E, Tonino R et al. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2002; 77 (10): 1044–52.
15. Gur A, Cevik R, Nas K. Comparison of zinc excretion and biochemical markers of bone remodelling in the assessment of the effects of alendronate and calcitonin on bone in postmenopausal osteoporosis. Clin Biochem 2005; 38 (1): 66–72.
16. Heaney RP. Advances in therapy for osteoporosis. Clin Med Res 2003; 1 (2): 93–9.
17. Hughes DE, Wright KR, Uy HL et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995; 10: 1478–87.
18. Lanza F, Sahba B, Schwartz H et al. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo–controlled endoscopy study. Am J Gastroenterol 2002; 97 (1): 58–64.
19. Lawrence VA, Hilsenbeck SG et al. Medical complications and outcomes after hip fracture repair. Arch Intern Med 2002; 162: 2053–7.
20. Liberman UA, Weiss SR, Broll J et al. Alendronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333 (22): 1437–43.
21. Mashiba T, Turner CH, Hirano T et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001; 28 (5): 524–31.
22. Mauck KF, Clarke BL. Diagnosis, screening, prevention, and treatment of osteoporosis. Mayo Clin Proc 2006; 81 (5): 662–72.
23. Nancollas GH, Tang R, Gulde S et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006; 38 (5): 617–27.
24. Nguyen TV, Center JR, Eisman JA. Osteoporosis: underdiagnosed and undertreated. Med J Aust 2004; 180 (5): 18–22.
25. Painter SE, Kleerekoper M, Camacho PM. Secondary osteoporosis: a review of the recent evidence. Endocr Pract 2006; 12 (4): 436–45.
26. Pols HA, Felsenberg D, Hanley D et al. A multinational randomized trial of the effects of alendronate on bone mineral density and fracture risk in postmenopausal women with low bone mass: result of the FOSIT study. Osteoporos Int 1999; 9 (5): 461–8.
27. Rizzoli R, Greenspan SL, Bone G et al. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Mineral Research 2002; 17 (11): 1988–96.
28. Rogers MJ. New insights into molecular mechanisms of action of bisphosphonates. Curr Pham Des 2003; 9: 2643–58.
29. Van Staa T, Leufkens H, Abenhaim L et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15: 993–1000.
30. Van Staa T, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis. Osteoporos Int 2002; 13: 777–87.
31. Woolf AD. An update on glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 2007; 19: 370–5.

Е.В.Бирюкова

Кафедра эндокринологии и диабетологии ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава России